Renal Impairment Study

Clinical Trial, Phase I Clinical Trial

Official title:
Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design

Status Completed

Clinical Trial Summary

The study will investigate the pharmacokinetics of BAY1142524 in subjects with mild to severe renal impairment compared to age; weight, and gender-matched healthy subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03402438
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 1
Start date	February 12, 2018
Completion date	March 19, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02262663` - Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan	Phase 1
Completed	`NCT02456129` - Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan	Phase 1
Completed	`NCT03484585` - Rogaratinib (BAY1163877) Human Mass Balance Study	Phase 1
Active, not recruiting	`NCT04375267` - 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours	Phase 1